Interleukin Genetics Inc. (NYSE:ILI) launched a diagnostic test designed to detect genetic patterns associated with osteoporosis.
The Waltham, Mass.-based genetic test developer said its Bone Health Genetic Test, made by its Inherent Health subsidiary, determines a patient’s risk for developing vertebral fractures and low bone mineral density.
Interleukin said it developed the test using data from a clinical study of 2,500 people indicating that certain genetic variations are associated with the risk of spine fracture or low BMD, according to a press release.
In April, the company touted a clinical study of 1,200 Asian women showing that Korean women are 70 percent more disposed to vertebral fracture if they carry a genetic variation in the IL-10 gene.
Interleukin also has a weight management genetic test it says can help people lose weight by tailoring their diets to their genetic makeup. The Interleukin test divides patients into three genotype categories, according to their predisposition to respond to either low fat, low carbohydrate or macronutrient-balanced diets.